KRAS and non-small cell lung carcinoma: Pre-clinical studies associated entrectinib resistance with the acquisition of a KRAS p.G12C mutation and amplification of both KRAS and FGFR3 in HCC78, an NSCLC cell line bearing a ROS1 fusion8.